BioCentury | Jun 26, 2020
Politics, Policy & Law

Illumina, BGI litigation not yet at risk of getting drawn into U.S.-China dispute

Despite the high-profile nature of the patent dispute between Illumina and Chinese competitor BGI Genomics, two of the largest players in next-generation sequencing, there is no reason to believe it will become embroiled in the...
BioCentury | Mar 31, 2020
Product Development

COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial

FDA’s emergency use authorization for a Qiagen test Tuesday comes amid a flurry of advancements in therapeutic, vaccine and diagnostic COVID-19 programs, including GigaGen’s unveiling of a polyclonal antibody program derived from convalescent COVID-19 patients....
BioCentury | Mar 31, 2020
Finance

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

With its largest venture and growth capital fund to date, a $450 million vehicle, Gilde Healthcare is the latest European VC seeking to take bigger stakes in start-ups than it previously had sought, sometimes investing...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said Thierry Bernard will become the permanent CEO after serving on an interim basis since October. Bernard, who joined Qiagen in 2015 as SVP of the molecular diagnostics business area, takes...
BioCentury | Mar 17, 2020
Product Development

FDA expanding U.S. COVID-19 test capacity, industry ramping up to meet demand

The U.S. FDA Monday night announced new policies and Emergency Use Authorizations to expand COVID-19 test capacity. Diagnostics companies are also stepping up to meet demand. Qiagen is increasing production of RNA extraction kits, and...
BioCentury | Mar 13, 2020
Politics, Policy & Law

U.S. moves to unlock COVID-19 test capacity

The U.S. government and industry took steps Friday to unlock COVID-19 testing capacity, including authorizing a commercial test, allowing New York to regulate tests conducted in the state, and funding development of two rapid diagnostics....
BioCentury | Mar 10, 2020
Finance

Diagnostics companies survive Monday’s market rout

Large diagnostics companies with COVID-19 testing capabilities weathered Monday’s sell-off better than biotechs developing therapies and vaccines for the virus. Major indexes fell due to continued fears over the COVID-19 outbreak and a steep drop...
BioCentury | Mar 4, 2020
Deals

Thermo Fisher takes out Qiagen for $11.5B

After vowing late last year to remain independent, Qiagen has reversed course and agreed to be acquired by Thermo Fisher in an $11.5 billion cash deal. The deal value surpasses the 36-year-old Dutch molecular diagnostics...
BioCentury | Feb 27, 2020
Product Development

COVID-19 roundup: Qiagen ships diagnostic to China; plus Gilead starts own remdesivir trials and Ascletis clinical update

Qiagen said Wednesday it is seeking emergency FDA clearance for its coronavirus diagnostic. Separately, Gilead started a pair of Phase III trials of remdesivir to treat COVID-19, bringing the total number of trials testing the...
BioCentury | Feb 13, 2020
Product Development

COVID-19 update: Remdesivir readout in weeks; hospital-use diagnostic under development; antibodies advancing

Initial signals from two ongoing trials in China of Gilead’s remdesivir to treat COVID-19 should be available in a few weeks, Marie-Paule Kieny said at a WHO press conference Wednesday. Assistant Director-General Kieny co-chaired the...
Items per page:
1 - 10 of 739
BioCentury | Jun 26, 2020
Politics, Policy & Law

Illumina, BGI litigation not yet at risk of getting drawn into U.S.-China dispute

Despite the high-profile nature of the patent dispute between Illumina and Chinese competitor BGI Genomics, two of the largest players in next-generation sequencing, there is no reason to believe it will become embroiled in the...
BioCentury | Mar 31, 2020
Product Development

COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial

FDA’s emergency use authorization for a Qiagen test Tuesday comes amid a flurry of advancements in therapeutic, vaccine and diagnostic COVID-19 programs, including GigaGen’s unveiling of a polyclonal antibody program derived from convalescent COVID-19 patients....
BioCentury | Mar 31, 2020
Finance

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

With its largest venture and growth capital fund to date, a $450 million vehicle, Gilde Healthcare is the latest European VC seeking to take bigger stakes in start-ups than it previously had sought, sometimes investing...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said Thierry Bernard will become the permanent CEO after serving on an interim basis since October. Bernard, who joined Qiagen in 2015 as SVP of the molecular diagnostics business area, takes...
BioCentury | Mar 17, 2020
Product Development

FDA expanding U.S. COVID-19 test capacity, industry ramping up to meet demand

The U.S. FDA Monday night announced new policies and Emergency Use Authorizations to expand COVID-19 test capacity. Diagnostics companies are also stepping up to meet demand. Qiagen is increasing production of RNA extraction kits, and...
BioCentury | Mar 13, 2020
Politics, Policy & Law

U.S. moves to unlock COVID-19 test capacity

The U.S. government and industry took steps Friday to unlock COVID-19 testing capacity, including authorizing a commercial test, allowing New York to regulate tests conducted in the state, and funding development of two rapid diagnostics....
BioCentury | Mar 10, 2020
Finance

Diagnostics companies survive Monday’s market rout

Large diagnostics companies with COVID-19 testing capabilities weathered Monday’s sell-off better than biotechs developing therapies and vaccines for the virus. Major indexes fell due to continued fears over the COVID-19 outbreak and a steep drop...
BioCentury | Mar 4, 2020
Deals

Thermo Fisher takes out Qiagen for $11.5B

After vowing late last year to remain independent, Qiagen has reversed course and agreed to be acquired by Thermo Fisher in an $11.5 billion cash deal. The deal value surpasses the 36-year-old Dutch molecular diagnostics...
BioCentury | Feb 27, 2020
Product Development

COVID-19 roundup: Qiagen ships diagnostic to China; plus Gilead starts own remdesivir trials and Ascletis clinical update

Qiagen said Wednesday it is seeking emergency FDA clearance for its coronavirus diagnostic. Separately, Gilead started a pair of Phase III trials of remdesivir to treat COVID-19, bringing the total number of trials testing the...
BioCentury | Feb 13, 2020
Product Development

COVID-19 update: Remdesivir readout in weeks; hospital-use diagnostic under development; antibodies advancing

Initial signals from two ongoing trials in China of Gilead’s remdesivir to treat COVID-19 should be available in a few weeks, Marie-Paule Kieny said at a WHO press conference Wednesday. Assistant Director-General Kieny co-chaired the...
Items per page:
1 - 10 of 739